Cytokinetics vs Foghorn Therapeutics
CYTK and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYTK and FHTX compare
Foghorn Therapeutics is the larger company, worth 17 times as much as Cytokinetics ($123M against $7.3M).
Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus 29.9% for Cytokinetics).
Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −687% at Cytokinetics.
Foghorn Therapeutics scores higher on the StockData Score (11 against 5 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYTK | FHTX |
|---|---|---|
| Size and price | ||
| Market cap | $7.3M | $123M |
| Share price | $56.13 | $2.07 |
| Change, 1 year | −14.9% | −54.3% |
| Change, 5 years | 37.4% | −84.9% |
| Beta (5Y) | 0.85 | 1.87 |
| Employees | 673 | 106 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 29.6× |
| P/S | 0.1× (better) | 1.1× |
| EV/EBITDA | – | 11.1× |
| FCF yield | −8115% | −68.1% (better) |
| Fair value | – | $2.09 |
| Margin of safety | – | 0.79% |
| Growth | ||
| Revenue growth (TTM) | 29.9% | 357% (better) |
| Revenue growth, 5Y average | 9.5% | 135% (better) |
| Profitability | ||
| Operating margin | −625% | 2.1% (better) |
| Net margin | −687% | 8.4% (better) |
| FCF margin | −520% | −74.6% (better) |
| Financial health | ||
| Current ratio | 3.36 | 4.24 (better) |
| Altman Z-score | −3.80 | −2.66 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 115% | 75.6% |
| Held by insiders | 0.68% | 36.3% |
| Insider net buying, 12 months | −$51.5M | – |
| Short interest, % of float | 13.0% | 6.0% |
Go deeper
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.